Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Back to patent action
View:
Post by Pandora on Jun 29, 2022 12:26am

Back to patent action

I still do not understand what it all means but it continues to move ahead.
The Notice of Allowance was passed today and has been mailed out:

Select New Case Application Data Transaction History Image File Wrapper Continuity Data Published Documents Correspondence Data Assignments Display Download References
 Transaction History
Mail Notice of Allowance
Date Transaction Description
06-28-2022 Email Notification
06-28-2022 Mail Notice of Allowance
16/610,991 VACCINE CONTAINING CANCER CELLS INACTIVATED BY PHOTODYNAMIC TREATMENT WITH METAL-BASED COORDINATION COMPLEXES, AND IMMUNOTHERAPY METHOD USING SAME T1081/20076 Printer Friendly Version

Available Documents
Mail Room Date sort by Mail Room Date What is a Document Code Document Code sort by Document Code Document Description sort by Document Description What is a Document Code Document Category sort by Document Category Page Count sort by Page Count Download the selected documents as PDF
06-28-2022 NOA Notice of Allowance and Fees Due (PTOL-85) PROSECUTION 7
06-28-2022 EXIN Examiner Interview Summary Record (PTOL - 413) PROSECUTION 1
06-28-2022 892 List of references cited by examiner PROSECUTION 1
06-28-2022 SRFW Search information including classification, databases and other search related notes PROSECUTION 1
06-28-2022 IIFW Issue Information including classification, examiner, name, claim, renumbering, etc. PROSECUTION 3
06-28-2022 SRNT Examiner's search strategy and results PROSECUTION 1
06-28-2022 1449 List of References cited by applicant and considered by examiner PROSECUTION 6
06-28-2022 SRNT Examiner's search strategy and results PROSECUTION 28
06-28-2022 BIB Bibliographic Data Sheet PROSECUTION 1
06-28-2022 1449 List of References cited by applicant and considered by examiner
Comment by Lesalpes29 on Jun 29, 2022 6:42am
It seems that TLT will have a new patent when the fees will be paid. It’s my understanding. 
Comment by Infinity on Jun 29, 2022 9:47am
Pandora, I believe a patent application by Theralase is approved. Time to consult with Patent Lawyers regarding the "Rights" and pay the fees and receive patent in due course. Rights typically pertain to future use of the patent for different purpose or opportunities that may arise in the future. More like forecasting the future use of this patent. Following info gathered from the Blog ...more  
Comment by Pandora on Jun 29, 2022 1:22pm
Infinity, everything you have posted is correct and yes the patent has been issued a "Notice of Allowance which is the primary step of "approval" and once the fees are paid, etc. the patent will be issued. My concern the last time I posted regarding the patent moving forward was something called a "Terminal Disclaimer" being filed as part of the process. It is something I ...more  
Comment by Pandora on Jun 29, 2022 1:24pm
I guess the other option is that we just forget there is some little terminology included and be happy with the fact that they are getting a new patent approval for a vaccine. :-))
Comment by Infinity on Jun 29, 2022 9:29pm
Pandora, Thanks for sharing the research.  I am not sure about the Legal terminology in the event of a dispute arising etc.  I understand that the Patent is for a Vaccine for treating cancer??.  I believe Theralase applied for a Patent using the cancer cells de-activated by using Rutherin+ TLD 1433...for treatment of Colo - rectal cancers.  I did not see any news from theralase ...more  
Comment by Pandora on Jun 29, 2022 11:14pm
Infinity although I have trouble with the legalese I might say that it is a simple form compared to the written dialogue of a medical patent. I could paste the whole patent literature here but I'm not sure anyone would have the interest to go through it -- and it is very long and formatted too tightly to be easy reading. It is rather deep. The patent dialogue has two major sections, " ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250



USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse